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Drug interactions äs a cause of
overanticoagulation on phenprocoumon or
acenocoumarol predominantly concern
antibacterial drugs
Background: The risk of hemorrhage when coumarin anticoagulants are used sharply increases wheii the
international norinalized ratio (INR) is >6.0. Such overanticoagulation niay be caused by drug interac-
tions. We performed a case-control study aniong previously stable outpatients of an anticoagulation clinic
using phenprocoumon or acenocoumarol to identify changes in the use of potentially interacting drugs
related to overanticoagulation.
MetboAs: Three hundred case patients with INR values >6.0 were compared with 302 randomly selected
matched control subjects with INR values within the target zone. Information on changes in the use of
87 potentially interacting drugs in the 4 weeks before the index day was collected by interviewing patients
and by reviewing the anticoagulant medical record.
Results: Forty-five potentially interacting drugs were not used in the 4-week study period, and only 15
drugs were used by at least 10 patients. For a number of drugs, too few patients had a relevant change in
use to judge their association with overanticoagulation. A course of a combination product of sul-
famethoxazole and trimethoprim strongly increased the risk of overanticoagulation (adjusted odds ratio,
24.2; 95% confidence interval [CI], 2.8 to 209.1; population attributable risk percentage [PAR%], 5.7%),
especially in patients receiving acenocoumarol. Penicillins were associated with a risk of overanticoagula-
tion of 2.4 (95% CI, 1.00 to 5.5); the corresponding PAR% was 3.4%. The effect was confined to amoxi-
cillin (INN, amoxicilline) plus clavulanic acid.
Conclusion: Drug interactions äs a cause of overanticoagulation predominantly concerned antibacterial
drugs. If possible, the use of sulfamethoxazole-trimethoprim and amoxicillin plus clavulanic acid should
be avoided in patients receiving couniariiis. If there is no therapeutic alternative available, increased mon-
itoring of INR values is warranted to prevent overanticoagulation and potential bleeding complications.
(Clin Pharmacol Ther 2001;69:451-7.)
Fernie J. A. Penning-van Beest, MSc, Erik van Meegen, MD, Frits R. Rosendaal, MD, PhD,
and Bruno H. Stricker, MD, PhD Rotterdam, The Hague, and Leiden, The Netherland<;
From the Pharmacoepidemiology Unit, Departments of Internal Med
icme and Epidemiology and Biostatistics Erasmus Umversity Med
ical Center, Rotterdam, the Red Cross Anticoagulation Clinic and
the Drug Safety Unit, Inspectorate for Health Care, The Hague, and
the Hemostasis and Thrombosis Research Center, Department of
Clmical Epidemiology, Leiden Umversity Medical Center, Leiden
Supported by the Red Cioss Anticoagulation Clinic, The Hague and
the Mmistry of Health, Weifare and Sports
Received for pubhcation Dec 7, 2000, accepted March 13 2001
Reprint requests Bruno H Stricker, PhD, Pharmacoepidemiology
Unit, Room L448, Department of Internal Mediane Erasmus Um
versity Medical Center Rotterdam, PO Box 2040, 3000 CA Rot-
terdam, The Netherlands
Copyright © 2001 by the American Society for Chmcal Pharmacology
and Therapeutics
0009-9236/200l /$35 00 + 0 13/1/115723
doi 10 1067/mcp2001 115723
Coumaim anticoagulants are widely used in the pie-
vention of venous and artenal thromboembohsm '
These drugs mduce anticoagulation by antagonizing
vitamm K and thereby impainng the biological activ-
ity of the vitamm K-dependent coagulation factois
(factor II, VII, IX, and X) 2 Opposite their benefit
Stands the risk of hemorrhage,3 which is strongly asso-
ciated with the intensity of anticoagulation and sharply
increases when the international normahzed ratio
(INR) is > 6 0 4 5 Such oveianticoagulation may be
caused by drug-drug interactions, and coumarin anti-
coagulants aie extremely susceptible to drug-drug
inteiactions because of their nairow therapeutic lange 6
Cntical penods aie when a patient stabihzed on an anti-
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coagulant regimen Starts treatment with an mteracting
drug or when a patient stabilized on a regimen of an
interacting drug and an anticoagulant has the interact-
ing drug withdrawn.7 A considerable number of drug
interactions with coumarin anticoagulants, based on
case reports and small-scale experiments, have been
reported and summarized.6"9 However, epidemiologic
studies that quantify the role of drug interactions in
overanticoagulation in a nonselected population on
coumarins under everyday circumstances are scarce.
Therefore we conducted a prospective nested case-
control study among outpatients of an anticoagulation
clinic. We identified changes in the use of potentially
interacting drugs related to an INR >6.0 in previously
stable patients who were taking phenprocoumon or
acenocoumarol, and we calculated the corresponding
odds ratios (OR) and population attributable risk per-
centages (PAR%). This article is one of a series of 3
papers on risk factors for overanticoagulation. The
other 2 articles are based on the same study and con-
cern characteristics of anticoagulant therapy and
comorbidity and sociodemographic, lifestyle, and
dietary factors.
METHODS
Setting. In the Netherlands, anticoagulant therapy is
monitored by a network of more than 60 independently
operating specialized anticoagulation clinics that cover
more than 90% of the country.10·1' The study was per-
formed at the regional Red Cross Anticoagulation
Clinic, The Hague, which serves an area of nearly
700,000 inhabitants. All persons in this area with an
indication for anticoagulant therapy are referred to this
clinic.
Cohort definition. The study cohort consisted of all
patients treated with oral anticoagulants by the regional
Red Cross Anticoagulation Clinic, The Hague, between
December l, 1997, and June 14, 1999. All cohort mem-
bers were monitored until the first occurrence of an INR
>6.0, the end of their treatment, or the end of the study
period (ie, the day on which the planned number of case
patients was recruited), whichever came first.
Case patients and control subjects. Subjects for the
nested case-control study were identified daily from all
patients with an INR measurement on that day. Case
patients were defined äs cohort members with INR val-
ues >6.0. For each case patient, l control subject,
matched on therapeutic ränge, was randomly selected
from the cohort members with INR values within the
target zone (2.0 to 3.5 or 2.5 to 4.0), measured on the
same day äs the case patient (index day). Overantico-
agulation is often seen during initiation of anticoagu-
lant therapy and in unstable anticoagulation. Because
this was not our primary interest, only case patients and
control subjects with stable anticoagulation in the 3
months before the index day were eligible. Anticoagu-
lant therapy is considered to be effective and safe if the
patient is kept within the target zone for more than two-
thirds of the time.12·13 We therefore defined stable anti-
coagulation äs having at least 66% of the INR values
within the target zone and no INR values >5.5 in the 3
months before the index day. To judge stability, a min-
imum of 3 INR values had to be assessed in the 3
months before the index day. Case patients and control
subjects with a hospital admission in this period were
excluded because Information on anticoagulant control
during admission is often not available at the anticoag-
ulation clinic. We focused on sudden overanticoagula-
tion, therefore the INR preceding the assessment on the
index day had to be within the target zone. Because of
questions about medication and diet, the patients had
to be living independently and not making use of Meals
on Wheels. We were primarily interested in overanti-
coagulation, regardless of whether it was followed by
hemorrhage, therefore patients who came to the clinic
on the index day with a serious bleeding complication
were excluded because it might have promoted recall
bias.
Procedure. The study protocol was approved by the
Medical Ethics Committee of the Erasmus University
Medical Center Rotterdam. We planned to recruit 300
case patients and 300 control subjects to provide at least
an 80% power to detect a true OR of >2.0 for risk fac-
tors that had a prevalence of 7% among the control sub-
jects, with P < .05 used to reject the null hypothesis of
OR= 1.
Information on changes in drug use, potential con-
founding factors, and effect modifiers was collected
from the antiL^dgulant medical record, through the gen-
eral practitioner and the pharmacy, äs well äs by inter-
viewing the patient. The interview took place within 3
weeks after the index day at the private address of the
patient, making use of structured questionnaires with
mainly closed questions. The Interviewers were blinded
with respect to each patient's case or control Status and
the specific research hypothese's. This also applied to
the general practitioners and the pharmacists. Blinding
of the patients was not fully feasible because the INR
value was printed on their dosage list. To obviate this,
in the Information letter we referred to the problem of
overanticoagulation in a general sense.
Changes in drug use. The risk period was defined
äs the 4-week period before the index day. Patients were
asked to show all currently taken prescription and over-
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the-counter drugs and vitamin Supplements. The dosage
and frequency of use of these drugs and vitamins were
recorded. Patients were asked about dosage changes in
the risk period, drugs and vitamins that were started in
the risk period, and drugs and vitamins that were dis-
continued in the risk period. Information in the antico-
agulant medical record on dosage changes, Start, or dis-
continuation of a drug was also considered. Of all
patients, the medication history of the preceding 6
months was obtained from the pharmacy. This history
was used to judge the reliability of the patient interview
data and anticoagulant medical record data on changes
in drug use.
On the basis of overviews of drugs interacting with
anticoagulant therapy,6'8 69 drugs and 18 drug classes
were a priori considered to be potentially interacting
drugs. Because changes in drug use, rather than con-
tinuous drug use, pose a risk of overanticoagulation,7
the occurrence of the following situations was defined
for every patient by use of patient interview data and
anticoagulant medical record data: Start, dose increase,
or irregulär and infrequent use (ie, l or 2 times a week)
of a potentially interacting drug or vitamin that
enhances the anticoagulant effect, äs well äs discontin-
uation, dose reduction, or irregulär and infrequent use
of a potentially interacting drug or vitamin that dimin-
ishes the anticoagulant effect.
Cofactors. A change in drug use, especially a course
of antibacterial drugs and the use of analgesics, most
probably occurs in case of an acute illness or a relapse
of a chronic comorbidity. These situations may be
accompanied by fever or may result in a change in
weight, physical activity, dietary intake (and thereby
intake of vitamin K), or alcohol consumption. All of
these factors may affect the response to oral anticoag-
ulants2'9'14"18 and were therefore considered to be
potential confounders. The associations between these
cofactors and overanticoagulation are the main subjects
of the 2 other articles mentioned earlier.
Furthermore, effect modification by the type of anti-
coagulant may be present. Drugs may interact with
coumarin anticoagulants by inducing or inhibiting spe-
cific cytochrome P450 enzymes, especially cytochrome
P450 2C9 (CYP2C9).6·8-19 The difference in the struc-
ture of acenocoumarol and phenprocoumon, although
small, may have implications on the relative contribu-
tion of cytochrome P450 enzymes to their metabo-
lism.20 The risk of overanticoagulation when the use of
CYP2C9-mediated drugs changes therefore possibly
differs with the type of anticoagulant used.
Statistical analyses. Changes in the use of potentially
interacting drugs (vitamin Supplements included)
related to an INR value >6.0 were identified with use
of univariate conditional logistic regression analysis at
first. Because the unconditional analyses gave compa-
rable results but more Statistical power, we finally used
unconditional logistic regression analysis to compute
unadjusted OR values and their 95% CI values. In case
a risk factor was absent in either the case patients or
the control subjects, a Fisher exact test was performed
instead. To assess changes in drug use that were inde-
pendently associated with an INR value >6.0, all fac-
tors that were univariately associated at P < .10 were
included in a multiple regression model. Besides age,
sex, and the number of INR determinations in the pre-
ceding 3 months, cofactors that were univariately asso-
ciated with an INR value >6.0 were included if this
resulted in a change in one of the odds ratios of 5% or
more, starting with the most potent factor. Effect mod-
ification by the type of anticoagulant was studied by
performing stratified analyses.
To determine the importance of the independent risk
factors for overanticoagulation in the population, we
calculated the population attributable risk percentages
(PAR%) according to the following formula21:
PAR% = AR% · (proportion of exposed case patients)
with AR% = ([OR - 1]/OR) · 100
RESULTS
The nested case-control study included the planned
number of 300 case patients with a median INR of 6.8
and 302 control subjects with a median INR of 3.2. The
participation among case patients and control subjects
was 78% and 85%, respectively. Written informed con-
sent was obtained from every patient. The mean inter-
val between the index day and the interview was 14
days for case patients and for control subjects. Charac-
teristics of the study population are presented in Table
I. Fifty-five percent of the case patients and 66% of the
control subjects used phenprocoumon, and the others
used acenocoumarol. The mean number of prescription
and over-the-counter drugs regularly and frequently
used, besides the anticoagulant, and the number of
patients using health Supplements was similar for case
patients and control subjects.
Of 87 potentially interacting drugs or drug classes,
45 were not used by the study population in the 4-week
risk period and 27 were used by fewer than 10 patients.
The drugs and drug classes used by at least 10 patients
are listed in Table II; about one-third of the patients had
used acetaminophen (INN. paracetamol) in the risk
period and one-fourth had used 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase inhibitors; the remain-
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Table I. Characteristics of the study population*
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OR, Odds ratio, CI, confidence intervai
*Values are numbers unless mdicated otherwise
tPrescnbed and over-the-counter drugs, rcgularly and frequently used (ιέ, at least 3 times a week) besides the anticoagulant
mg drugs were used by fewer than 46 patients. A rele-
vant change in use in the risk period occurred in at least
10 patients each only for acetaminophen, doxycycline,
amoxicillin (INN, amoxicilline), amoxicillin plus
clavulanic acid, and sulfamethoxazole-trimethoprim.
Comparison of the Information on the start of antibac-
terial drugs given by the patient or mentioned in the
anticoagulant medical record with that subtracted from
the medication history revealed no substantial differ-
ences in either the case patients or the control subjects.
The associations between overanticoagulation and
changes in drug use are shown in Table III. A course of
antibacterial drugs was associated with an INR >6.0
(OR, 2.8; 95% CI, 1.8 to 4.5). In view of a difference
in mechanism of interaction and to be more informa-
tive, all antibacterial drugs were also studied individu-
ally. Sulfamethoxazole-trimethoprim most strongly
increased the risk of overanticoagulation. After adjust-
ment for confounding factors, the increased risk was
24.2 (95% CI, 2.8 to 209.1). The corresponding PAR%
was 5.7%. Penicillins were associated with an increased
risk of an INR >6.0 of 2.4 (95% CI, 1.00 to 5.5). Adjust-
ment for confounders did not change the OR. The
PAR% of overanticoagulation associated with the use
of penicillins was 3.4%. The effect of penicillins was
confined to amoxicillin plus clavulanic acid. Doxycy-
cline was only univariately associated with overantico-
agulation (OR, 2.3; 95% CI, 1.1 to 4.6). Fluoroquinolones
and clarithromycin were not related to an INR >6.0;
however, the number of patients was small. The strati-
fied analyses revealed that the effect of sulfamethoxa-
zole-trimethoprim on the risk of overanticoagulation
depended on the type of anticoagulant used and was
especially present in patients taking acenocoumarol.
The analgesic used mainly was acetaminophen. Its
use was associated with an increased risk of overanti-
coagulation of 1.5 (95% CI, 0.98 to 2.2). Adjustment
for confounding factors reduced the OR to 1.2.
DISCUSSION
We studied the role of drug jnteractions in overanti-
coagulation among outpatients of an anticoagulation
clinic. Half of the 87 potentially interacting drugs or
drug classes were not used by the study population and
only 15 drugs or drug classes were used by more than
10 patients. A relevant change in use in the risk period
was infrequent. A course of sulfamethoxazole-trimetho-
prim and the use of amoxicillin plus clavulanic acid,
however, were risk factors for overanticoagulation. The
clinical implication of our fmdings is the possibility of
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prevention or early detection of overanticoagulation,
and thus of bleeding complications, by considering the
use of antibacterial drugs other than sulfamethoxazole-
trimethoprim and amoxicillin plus clavulanic acid. If
there is no therapeutic alternative available, increased
monitoring of INR values is warranted, that is, measur-
ing the INR on the third day after the Start of the
antibacterial drug and, relative to this INR, 3 to 7 days
thereafter. Our study also suggests that acetaminophen
is a safe analgesic for patjents receiving oral anticoag-
ulants.
Many drugs postulated to interact with anticoagulant
therapy on the basis of case reports and small-scale
experiments were not used by our study population or
by fewer than 10 patients. This is a reassuring observa-
tion, suggesting that these drugs did not play a major
role in overanticoagulation in everyday circumstances.
In addition, a change in drug use occurred infrequently
for many of the 87 drugs. Although we could not judge
their association with overanticoagulation because of
the small numbers, this finding suggests that these
drugs played only a minor role in our study population.
Our results regarding the role of drugs in overantico-
agulation likely may be generalized because the kinds
of drugs used in our population is largely the same äs
those used in most other countries.
The types of coumarin used by our study population
were phenprocoumon and acenocoumarol. In many
countries warfarin is the coumarin of first choice. The
results of our study, however, will largely apply to these
countries äs well. First, interactions of a pharmacody-
namic nature on a receptor level occurring with one
anticoagulant may well apply to another anticoagulant.7
Second, the difference in half-life between coumarins
will influence the time of onset and the duration of
overanticoagulation6 but will not necessarily affect the
baseline risk. Third, drugs that interact by inducing or
inhibiting the cytochrome P450 isozyme CYP2C9 will
affect both acenocoumarol and warfarin.20
Two mechanisms have been suggested for antibi-
otic-associated hypoprothrombinemia.22 First,
antibacterial drugs affect the vitamin K Status by elim-
inating vitamin K-producmg microorganisms from
the colon. Second, certain antibacterial drugs directly
inhibit the synthesis of the vitamin K-dependent coag-
ulation factors. High-risk antibiotics are
cephalosporins that contain the jV-methylthiotetrazole
moiety. In patients receiving anticoagulant therapy,
sulfamethoxazole-trimethoprim may also increase the
anticoagulant effect by inhibiting the metabolism of
the anticoagulant by trimethopnm23 or by increasing
the plasma concentration of free coumarin by sul-
Table II. Potentially interacting drugs and drug classes







































































































HMG-CoA, 3-Hydroxy-3-methylglutaryl coen?yme A
*Start, dose increase, or irregulär and mfrequent use (le, l or 2 times a week)
ot an interacting drug enhancmg the anticoagulant effect or discontmuation
dose leduction, or irregulär and mfrequent use of an interacting drug dimin-
ishmg the anticoagulant effect
famethoxazole.24 The degree of Inhibition of the
metabolism may be different for acenocoumarol and
phenprocoumon.20 The results of our study are in
agreement with this theory. The underlying indication,
fever, and other illness-related factors may also be
responsible for an increase in the anticoagulant effect
when antibacterial drugs are used. After we adjusted
for these potential confounders. doxycycline was no
longer associated with overanticoagulation. Amoxi-
cillin plus clavulanic acid, however, remained a risk
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INR International noimalizcd ralio
^Values are numbcrs Those drugs lor which the nurnber of paüents with a relevant change m use was less than 3 are not mcluded m the table This concerns tetracy-
chne (l case patient/0 control subjects), mmocycline (O/I) , azithromycm (O/ I ) , cetaclor (O/I), ceftibuten (0/1), piroxicam (1/0), cisapnde (1/0), simvastatin (0/1),
pravastatin (0/2), gemllbro/il (I /O), cholcstyramme (INN colestyramme) (1/0) carbama/epme (1/0) phenytom (1/0), miconazole ( l / l ) , fluoxetme (0/2), chlorthahdone
(INN üllortahdone) (O/l) metromdazole (1/0)
TSultamethoxa7ole-tnmethopnm amoxicii l in plus t lavulanic acid, doxycychnc, acetammophcn, age, sex, the number of INR determmations m the precedmg 3
months, levei diarrhca, relapse ot congestive heart tailurc, lllness of the unnary tract, ehange m wcight and change m alcohol consumption were mcluded in the
model
factor. This difference may be caused by a difference
in effect on the intestinal microflora.
To our knowledge, epidemiologic studies on risk fac-
tors for overanticoagulation in a nonselected popula-
tion under everyday circumstances are scarce and were
only published for the first time in 1998. Two of 3 ear-
lier studies25·26 have some limitations. The third study27
was well performed; however, changes in drug use were
not studied individually. Newly started treatment with
potentiating drugs (all combined, half of which were
antibiotics) and the use of acetammophen were inde-
pendent determinants of an INR value >6.0. The latter
finding is in contrast with our study. This may possibly
be because we used a 4-week risk period, whereas that
study27 used only the precedmg week äs a potential risk
penod. Another difference between the study of Hylek
et al27 and our study is that the study population of
Hylek et al27 used warfarin, whereas our patients used
phenprocoumon or acenocoumarol. In addition, we
included only stable case patients and control subjects.
Finally, potential confounding by a change in weight,
physical activity, or alcohol consumption was not taken
into account in the study of Hylek et al.27
In conclusion, in this study among previously sta-
ble outpatients of an anticoagulation clinic using phen-
procoumon or acenocoumarol, drug interactions äs a
cause of overanticoagulation predominantly concerned
antibacterial drugs. If possible, the use of sulfamethox-
azole-trimethoprim and amoxiciilin plus clavulanic
acid should be avoided in patients taking coumarins.
If there is no therapeutic alternative available,
increased monitoring of INR values is warranted to
prevent overanticoagulation and potential bleeding
complications.
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